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Array analysisMutations in the RNA binding protein FUS (fused in sarcoma) have been linked to a subset of familial
amyotrophic lateral sclerosis (ALS) cases. The mutations are clustered in the C-terminal nuclear localization
sequence (NLS). Various FUS mutants accumulate in the cytoplasm whereas wild-type (WT) FUS is mainly
nuclear. Here we investigate the effect of one ALS causing mutant (FUS-ΔNLS, also known as R495X) on
pre-mRNA splicing and RNA expression using genome wide exon-junction arrays. Using a non-neuronal sta-
ble cell line with inducible FUS expression, we detected early changes in RNA composition. In particular, mu-
tant FUS-ΔNLS increased calcium/calmodulin-dependent protein kinase II inhibitor 2 (CAMK2N2) at both
mRNA and protein levels, whereas WT-FUS had no effect. Chromatin immunoprecipitation experiments
showed that FUS-ΔNLS accumulated at the CAMK2N2 promoter region, whereas promoter occupation by
WT-FUS remained constant. Given the loss of FUS-ΔNLS in the nucleus through the mutation-induced trans-
location, this increase of promoter occupancy is surprising. It indicates that, despite the obvious cytoplasmic
accumulation, FUS-ΔNLS can act through a nuclear gain of function mechanism.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease
characterized by the progressive loss of motor neurons in the central
nervous system. Recent studies found that mutations in the RNA
binding protein FUS (fused in sarcoma) can cause a subset of heredi-
tary forms of ALS in a dominant fashion [1,2]. It has been largely
unknown how FUS mutations cause ALS.
FUS, also known as TLS (translocated in sarcoma) and as hnRNP
P2, is a nucleic acid binding protein that is mainly nuclear, but can
shuttle between the cytosol and the nucleus. FUS has been implicated
in multiple steps of mRNA metabolism, including transcriptional
regulation, regulation of RNA processing, and RNA export [3–7]. FUS
contains several domains that can bind to nucleic acids including an
RNA recognition motif that binds both to DNA and RNA [8], which
partially explains the multiple roles in gene expression.
Genomic translocation affecting FUS can result in cancer, especially
liposarcomas [9,10]. In these genomic rearrangements, the promoter18592572283.
1 31 8524 605.
stamms-lab.net (S. Stamm).
rights reserved.and N-terminal part of FUS is translocated to the C-terminal domain
of various DNA-binding transcription factors, resulting in a fusion
protein with a strong transcriptional activation domain (reviewed in
[11]). This indicates a role of FUS in gene transcription.
The familial ALS related mutations are clustered in the C-terminal
region, which was later determined as a nuclear localization
sequence (NLS) [12–14]. Mutations in the NLS decrease the nuclear
import and cause cytoplasmic accumulation of the mutant FUS
protein. In particular, the FUS-ΔNLS mutation lacks the NLS and
causes a relatively aggressive ALS clinical phenotype with an early
onset [14]. It has been proposed that the loss of a nuclear function
or the gain of a cytosolic function or both can be the possible cause
for the disease [15–17].
Recent studies have reported thousands of RNA targets that can
bind to FUS [18–20]. The structure of the RNA recognition motif of
FUS shows a non-canonical nucleic acid binding site and supports
the relatively low speciﬁcity binding of RNAs to FUS [8]. To gain
insight into how FUS mutations may interfere with mRNA transcrip-
tion and processing, we performed genome wide exon junction
array studies using stably transfected HEK293 cells with inducible
FUS expression. We speciﬁcally concentrated on early changes in
gene expression. Amongmore than 100 genes showing small changes
after 24 h of FUS expression, calcium/calmodulin-dependent protein
kinase II inhibitor 2 (CAMK2N2) showed the most striking difference
between wild type and mutant FUS. The change of CAMK2N2 was
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munoprecipitation experiments showed that FUS-ΔNLS accumulated
at the CAMK2N2 promoter region, whereas promoter occupation by
WT-FUS remained constant. The results from this study suggest that a
nuclear gain of function could also be an underlying mechanism con-
tributing to FUS mutation induced alterations.
2. Material and methods
2.1. Cell culture
HEK293 stable cells with inducible WT GFP-FUS and FUS-ΔNLS
expression have been described before. They were created by
FRT-mediated recombination into a single genomic locus. After antibi-
otic selection, the cells remained pooled to avoid clonal bias [14]. The
cells were cultured in DMEM with 10% TET-tested fetal bovine serum
(Atlanta Biologicals, s10350H), 2 mM L-glutamine (Gibco, 25030),
15 μg/ml blasticidin (Invitrogen, R210-01), 150 μg/ml hygromycin B
(Invitrogen, 10687-010), and 1% penicillin and streptomycin solution.
Doxycyline (Clontech, 1 μg/ml) was added to induce the expression of
GFP-FUS 6, 24, or 48 h before harvest.
2.2. Array analysis
RNA was isolated using Qiagen kits. Its quality was determined by
RNA integrity (RIN) number analysis and samples with a RIN > 9.5
were used following the Affymetrix labeling procedure.
For the analysis, the signal from Affymetrix human junction arrays
(HJAY) was normalized using the “Probe scaling” method. The back-
ground was corrected with ProbeEffect from GeneBase [21]. The gene
expression index was computed from probes that were selected using
ProbeSelect fromGeneBase [21]. The gene expression signals were com-
puted using these probes. Genes were considered expressed if themean
intensity was ≥500. Genes were considered regulated if 1) they were
expressed in at least one condition (i.e., VPA and/or control); 2) the
fold-change was greater or equal than 1.5 and; 3) the unpaired t-test
p-value between gene intensities was ≤0.05. For each probe, a
splicing-index was computed. Unpaired t-tests were performed to
determine the difference in probe expression between the two samples
as described previously [22]. Probe p-values in each probeset were then
summarized using Fisher's method. Using annotation ﬁles, splicing
patterns (cassette exons, 5′/3′ alternative splice sites and mutually
exclusive exons) were tested for a difference between isoforms,
selecting the ones with a minimum number of regulated probesets
(with a p-value ≤ 0.01) in each competing isoform (at least one third
of “exclusion” probesets have to be signiﬁcant; at least one third of
“inclusion” probesets have to be signiﬁcant and show an opposite regu-
lation for the splicing-index compared to the “exclusion” probesets). For
example, for a single cassette exon, the exclusion junction and at least
one of the three inclusion probesets (one exon probeset and two inclu-
sion junction probesets) have to be signiﬁcant and have to show an
opposite regulation for the splicing-index.
2.3. RT-PCR
Total RNA from HEK293 cells was extracted using the GenElute
Mammalian Total RNA Miniprep Kit (Sigma) according to the
manufacturer's instructions. cDNAs were synthesized from 1 μg of
each RNA using SuperScript® III Reverse Transcriptase (Life Technol-
ogies). Reverse transcriptase-polymerase chain reaction (RT-PCR) ex-
periments were carried out using 1 μl of each cDNA as template and
speciﬁc primers. Products were visualized on gel electrophoresis
after ethidium bromide staining. PCR primers were as follows:
β-ACTIN_FOR: AGAGCTACGAGCTGCCTGAC; β-ACTIN_REV: GGA




HEK293 cells were lysed and sheared by sonication in a 0.1%
NP-40/PBS (Sigma) lysis buffer to generate cellular chromatin frag-
ments of 400–500 bp. The chromatin was immunoprecipitated for
14–16 h at 4 °C using antibodies against GFP coupled to sepharose
(GFP-Trap_A, Chromotek). After the incubation, chromatin immu-
noprecipitates were puriﬁed, then 2 μl of each sample were ana-
lyzed by real-time PCR. The real-time PCR was carried out in the
Stratagene Mx3005P (Agilent Technologies), using SYBR green re-
agent (Life Technologies). The relative expression was estimated
as follows: 2Ct(reference) − Ct(sample), where Ct (reference) and Ct
(sample) were input DNA and speciﬁc histone modiﬁcation chroma-
tin, respectively. For each experiment, at least three immunoprecip-
itations were analyzed.
2.5. Antisera
Mousemonoclonal anti-FUS antibody (sc-47711) and goat polyclonal
anti-β-actin (sc-459) were purchased from Santa Cruz Biotechnology.
The CAMK2N2 antibody (N-term) was a peptide afﬁnity puriﬁed rabbit
polyclonal antibody (Pab) (AP11140a) from Abgent.
2.6. Transfection
HEK293 cells were seeded in 6 well plates, and were transfected
with pEGFP-C3 expression plasmids containing the wild type or
ΔNLS FUS cDNA using lipofectamine (Invitrogen) according to the
manufacturer's instructions [13].
2.7. Quantiﬁcation and statistical analysis
Quantiﬁcation and statistical analysis were performed using Quantity
One® 1-D Analysis Software (Biorad). Results are presented as
means ± S.D. Differences between means in two groups were com-
pared using the Student's t test. A 5% or 1% signiﬁcance level and
95% or 99%, respectively, conﬁdence interval were used in the sta-
tistical analysis.
3. Results
3.1. Characterization of stable cell lines with inducible expression of FUS
To determine the molecular role of WT-FUS as well as FUS-ΔNLS,
we chose stable HEK293 cell lines with Tet-On inducible expression
of either human WT-FUS or FUS-ΔNLS (Fig. 1A). Both proteins were
GFP-tagged to allow discrimination from endogenous FUS that is
expressed in all cells [14]. After 6 h of induction, the expression of
bothWT and FUS-ΔNLS started becoming evident (Fig. 1B). The exog-
enous GFP-FUS expression was comparable to the endogenous FUS
expression in the cells.
The FUS-ΔNLS variant was detected predominantly in the cyto-
plasm in familial ALS patient tissues. This feature is reﬂected by the
cytosolic accumulation of GFP tagged FUS variants in our cell culture
system (Fig. 1C). In contrast, WT-FUS is mainly nuclear. We noted
that GFP tagged FUS-ΔNLS still showed detectable nuclear staining
when it was expressed at the relatively low levels in these cells.
This inducible cell culture system offers comparable WT and mutant
FUS expression levels, which likely mimics the situation in human
ALS patients.
Fig. 1. Expression of GFP-FUS and GFP FUS-ΔNLS in stable cell lines. A. Domain structure of FUS and FUS-ΔNLS. B. Protein expression after FUS and FUS-ΔNLS induction. HEK293 cells
were stably transfected with GFP-FUS and GFP-FUS-ΔNLS expression constructs. The cells were induced with doxycycline for the times indicated. Western blots were performed
with an anti FUS antiserum and an anti-actin serum as a loading control. C. Intracellular localization of the FUS variants. The detection of the overexpressed proteins was through
their GFP tag. The cells were counterstained with DAPI. The size bar is 10 μm.
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FUS is part of the hnRNP complex and can bind both to single and
double stranded DNAs, as well as to RNA [11]. Since a signiﬁcant
amount of FUS-ΔNLS leaves the nucleus and accumulates in the cyto-
sol, we hypothesized that the mutation will cause a change in gene
expression. We therefore analyzed changes in mRNA expression
using Affymetrix genome wide exon junction arrays. In addition to
detecting changes in alternative splicing, exon junction arrays are a
robust tool to monitor overall gene expression, as each mRNA is
detected by multiple probes located in all mRNA regions. To identify
only early changes, we compared 24 h of induction, when both
WT-FUS and FUS-ΔNLS started to express. We concentrated on early
changes to avoid detection of secondary effects that are not directly
caused by FUS-ΔNLS overexpression. To minimize effects caused by
different growth conditions, all cells were seeded at the same
sub-conﬂuent density prior to doxycyclin induction.
Three datasets were generated for 24 h of induction. We measured
gene expression in cells expressing GFP, WT-FUS and FUS-ΔNLS. These
expression levels where then compared and changes larger than 1.5
fold with a p-value smaller than 0.05 were compared (Fig. 2). Compar-
ing GFP overexpression with wild type indicated ﬁve changes (Supple-
mentary Table 1). This low number reﬂects that a modest increase of
WT-FUS expression (approximately two fold since the GFP-FUS is com-
parable to the endogenous FUS, Fig. 1B) has no strong effect at the
timeframe of the experiment. Comparing FUS-ΔNLS with GFP indicated
156 changes (Supplementary Table 3), which suggested that FUS-ΔNLS
had a slightly stronger inﬂuence on gene expression. Finally, compar-
ing FUS-ΔNLS with FUS-WT showed 43 changes (Supplementary
Table 2). This comparison resembles most strongly the situation in
humans, where the mutant is expressed together with WT-FUS.
There are 23 changes common to the datasets when overexpression
of FUS-ΔNLS is compared to WT-FUS and uninduced cells, respectively
(Fig. 2).
An analysis of KEGG pathways did not indicate pathways that are
changed in a statistically signiﬁcant pathway (p b 10−3). The arrays
indicated only one change in alternative splicing with high conﬁdencein the comparison of FUS-ΔNLS with GFP, which could however not
be validated by RT-PCR (Supplementary Table 3, Pathway analysis tab).
Together, these data suggest that induction of FUS-ΔNLS has a
stronger effect on gene expression than expressing WT-FUS. The
low number of changes suggests that we monitor only early, direct
changes in FUS-ΔNLS dependent modiﬁcation in gene expression.
3.3. Differential expression of CAMK2N2
We next validated the effects of WT-FUS and FUS-ΔNLS
overexpression on gene expression using RT-PCRwith primers indicated
in Fig. 3D.We concentrated on the gene with themost pronounced con-
sistent differences during RT-PCR validations,whichwasCAMK2N2 (cal-
cium/calmodulin-dependent protein kinase II inhibitor 2). CAMK2N2
inhibits calcium/calmodulin-dependent protein kinase II, amajor signal-
ing molecule in the brain. It also interacts with the ARHGAP32 protein,
also called RICS for Rho GTPase activating protein 32 [23]. RICS promotes
GTP hydrolysis on RHOA, CDC42 and RAC1 small GTPases. As shown in
Fig. 3, WT-FUS down-regulated CAMK2N2 whereas FUS-ΔNLS up-
regulated the CAMK2N2mRNA levels after 6, 24 and 48 h of FUS expres-
sion. These differences between WT and mutant FUS expressing cells
were statistically signiﬁcant (Fig. 3C), when normalized to the actin
signal that was not inﬂuenced by FUS expression.
CAMK2N2 changes were highly reproducible in more than four
different experiments. Other changes shown in Supplementary
Table 1 varied between independent experiments and we did not
observe statistically signiﬁcant differences. These variations between
experiments likely reﬂect the early time points of the analysis that
were chosen to detect the early changes caused by the mutation.
We therefore identiﬁed a change in a mRNA encoding a regulatory
protein as a response to the expression of an ALS-causing variant of
FUS.
3.4. FUS-ΔNLS upregulates CAMK2N2 protein
To determine whether the changes on the RNA level are reﬂected
on the protein level, we analyzed CAMK2N2 protein levels after
Fig. 2. Summary of the array analysis. The Venn diagram shows pathways most affected by 24 h WT-FUS and FUS-ΔNLS overexpression. The changes of the arrays are shown in
Supplementary Tables 1–3.
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of WT-FUS, CAMK2N2 levels show no statistically signiﬁcant changes.
In contrast, when FUS-ΔNLS is overexpressed, we observe an about
2.5 fold induction on the protein level that reﬂects the increase on
the mRNA level.
3.5. FUS-ΔNLS upregulates CAMK2N2 in transient transfections
To rule out the selection of speciﬁc clones when making stable cell
lines, we tested the effect for FUS-ΔNLS on CAMK2N2 in transient trans-
fection assays. As shown in Fig. 5A, similar to the situation in stable cell
lines, WT-FUS had no effect on CAMK2N2 mRNA levels. In contrast, we
observed a steady increase of CAMK2N2 after transfecting FUS-ΔNLS
(Fig. 5B). After 48 h, CAMK2N2 is upregulated about 2.5 fold, similar
to the effect observed in stable cell lines.
We next determined the effect of FUS variants on the protein level
in transient transfections and observed an about two fold increase of
CAMK2N2 with FUS-ΔNLS, but no statistically signiﬁcant increase
with the wild type (Fig. 6A–C). The data suggest that FUS-ΔNLS
increases both mRNA and protein levels of CAMK2N2, both in stable
and transient transfections.
3.6. FUS-ΔNLS binds stronger to the CAMK2N2 promoter thanwild-type FUS
FUS has been shown to bind to DNA and to activate transcription
[3–5]. We therefore measured the binding of WT-FUS and FUS-ΔNLS
to the CAMK2N2 promoter. To compare WT and mutant FUS proteins,
we immunoprecipitated them using the GFP tag from the stable cell
lines. The cells were analyzed at 6 and 48 h, to capture the early
and strongest changes on the mRNA and protein levels. The levels of
CAMK2N2 promoter DNA bound to the immunoprecipitates were
determined using real-time PCR. As shown in Fig. 7, a 3.5 fold increaseof FUS-ΔNLS binding to the CAMK2N2 promoter was observed at 48 h
as compared to WT-FUS. Interestingly, there is a slight decrease after
6 h that precedes the strong increase, suggesting rearrangements at
the promoter. In contrast, WT-FUS bound to the promoter remains
constant. The data suggest that FUS-ΔNLS accumulates on the
CAMK2N2 promoter, which likely causes its induction.4. Discussion
FUS-ΔNLS has been identiﬁed as a rare mutation that causes ALS.
To gain insight into the molecular mechanism of this mutation, we
identiﬁed early changes in gene expression caused by FUS-ΔNLS
expression. This resembles the disease situation, where FUS-ΔNLS is
expressed in addition to WT-FUS. However, in the human system
one WT allele is substituted by a mutated allele. Our overexpression
system differs from other studies where WT-FUS was knocked out,
which resulted in multiple changes in pre-mRNA processing and
gene expression [19,20].
We detected only a few changes in gene expression that are small.
This is expected, as the disease has an onset of several years and we
concentrated only on early changes in gene expression to identify
directly regulated genes.
We did not ﬁnd any changes in pre-mRNA splicing, despite the
known involvement of FUS in this process [18]. This is likely due to
the early time point of analysis and the fact that we overexpressed
FUS, which did not drastically change the total amount of WT-FUS.
We found that the FUS-ΔNLS mutant causes an about two-fold
increase in CAMK2N2 mRNA and about 3.5 fold increase in protein
levels in non-neuronal cells. This was the only change that could be
validated in several independent RT-PCR experiments. It therefore
validated CAMK2N2 as this ﬁrst direct target of FUS-ΔNLS.
Fig. 3. The CAMK2N2 gene is changed after FUS-ΔNLS expression. A. RT-PCR detecting CAMK2N2 expression after WT-FUS was induced at the times indicated. B. RT-PCR detecting
CAMK2N2 expression after FUS-ΔNLS was induced at the times indicated. C. Quantiﬁcation of the CAMK2N2 signal after normalization to beta actin. D. Localization of the primer for
detection. Primers were F_CAMK2N2 and R_CAMK2N2.
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CAMK2N2 is an inhibitor of calmodulin dependent kinase 2 (CaMKII)
that arrests calmodulin on the kinase, which inhibits it. CAMK2N2
also physically interacts with the Rho GTPase activating protein 32
(RICS), a brain speciﬁc regulator for Rho-GAP signaling [23]. Both
CAMK2N2 and RICS are involved in signal transduction in the brain.
One mode of action for the FUS-ΔNLS variant is the disruption of
signaling networks, which could contribute to the disease in vivo.
CaMKII is known to phosphorylate AMPA-type glutamate receptors,Fig. 4. FUS-ΔNLS upregulates CAMK2N2 protein levels. A. After WT-FUS induction, CAMK2
times indicated. B. After FUS-ΔNLS induction, CAMK2N2 expression was detected by Weste
of the data is shown on the right.which are implicated in ALS [24,25]. It is therefore possible that
CaMKII-dependent changes in the phosphorylation of AMPA recep-
tors contribute to ALS.
Mechanistically, the change in CAMK2N2 expression is caused by
the binding of FUS-ΔNLS protein to the CAMK2N2 promoter. Since
WT-FUS binds to the promoter, it is likely that the mutant substitutes
endogenous WT-FUS and accumulates over time, which changes the
transcription. The molecular reason for this accumulation is unclear,
but it could involve an increase of binding to single stranded DNA inN2 expression was detected by Western blot in doxycycline induced cell lines for the
rn blot in doxycycline induced cell lines for the times indicated. C. The quantiﬁcation
Fig. 5. The CAMK2N2 gene is changed after FUS-ΔNLS transient expression. A. RT-PCR detecting CAMK2N2 expression after WT-FUS was transfected at the times indicated. 2 μg of
expression plasmid per 300,000 cells were used. B. RT-PCR detecting CAMK2N2 expression after FUS-ΔNLS was transfected at the times indicated. 2 μg of expression plasmid per
300,000 cells were used. C. Quantiﬁcation of the CAMK2N2 signal after normalization to beta actin.
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FUS-ΔNLS mutant stronger than the wild type. Therefore, despite the
cytosolic accumulation of FUS-ΔNLS, the protein could act through a
nuclear gain of function mechanism.
Together the data indicate that mutant FUS could change the ex-
pression of a regulatory protein CAMK2N2 by deregulation of its pro-
moter and that such changes could be involved in the etiology of ALS.
Array analysis of HEK293 cells stably transfected with constructs
expressing GFP, WT-FUS type and FUS-ΔNLS. Supplementary dataFig. 6. FUS-ΔNLS upregulates CAMK2N2 protein levels after transient transfections. A. After
indicated. B. After FUS-ΔNLS transfection, CAMK2N2 expression was detected by Western brelated to this article can be found online at http://dx.doi.org/10.
1016/j.bbadis.2013.03.015Funding
This work is supported by an Endowment from Linda and Jack Gill to
the University of Kentucky, funds by Dean Frederick de Beer, National
Institutes of Health grant R01NS077284 and the ALS Association grantWT-FUS transfection, CAMK2N2 expression was detected by Western blot at the times
lot at the times indicated. C. The quantiﬁcation of the data is shown on the right.
Fig. 7. Chromatin immunoprecipitations of CAMK2N2 DNA with FUS and FUS-ΔNLS. The stable cell lines were induced for 6 and 48 h and GFP-tagged FUS-wild type and FUS-ΔNLS
were immunoprecipitated using anti-GFP. Chromatin bound to the immunoprecipitates was detected by PCR using the primers located in the promoter regions, as indicated in the
cartoon on top. The graph represents three independent experiments. The expression level at time zero was set to one. The differences for FUS-ΔNLS are signiﬁcant, p b 0.05 (*) and
p b 0.01 (**), as indicated.
1135P. Convertini et al. / Biochimica et Biophysica Acta 1832 (2013) 1129–11356SE340 to H. Z. and NIH RO1 GM083187 and 5P20RR020171-08 to
S. S. L. J. H. was supported by the ALS Therapy Alliance.References
[1] C. Vance, B. Rogelj, T. Hortobagyi, K.J. De Vos, A.L. Nishimura, J. Sreedharan, X. Hu,
B. Smith, D. Ruddy, P. Wright, J. Ganesalingam, K.L. Williams, V. Tripathi, S.
Al-Saraj, A. Al-Chalabi, P.N. Leigh, I.P. Blair, G. Nicholson, J. de Belleroche, J.M.
Gallo, C.C. Miller, C.E. Shaw, Mutations in FUS, an RNA processing protein, cause
familial amyotrophic lateral sclerosis type 6, Science 323 (2009) 1208–1211.
[2] T.J. Kwiatkowski Jr., D.A. Bosco, A.L. Leclerc, E. Tamrazian, C.R. Vanderburg, C.
Russ, A. Davis, J. Gilchrist, E.J. Kasarskis, T. Munsat, P. Valdmanis, G.A. Rouleau,
B.A. Hosler, P. Cortelli, P.J. de Jong, Y. Yoshinaga, J.L. Haines, M.A. Pericak-Vance,
J. Yan, N. Ticozzi, T. Siddique, D. McKenna-Yasek, P.C. Sapp, H.R. Horvitz, J.E.
Landers, R.H. Brown Jr., Mutations in the FUS/TLS gene on chromosome 16
cause familial amyotrophic lateral sclerosis, Science 323 (2009) 1205–1208.
[3] A. Bertolotti, Y. Lutz, D.J. Heard, P. Chambon, L. Tora, hTAF(II)68, a novel
RNA/ssDNA-binding protein with homology to the pro-oncoproteins TLS/FUS
and EWS is associated with both TFIID and RNA polymerase II, EMBO J. 15
(1996) 5022–5031.
[4] A. Bertolotti, T. Melot, J. Acker, M. Vigneron, O. Delattre, L. Tora, EWS, but not
EWS-FLI-1, is associated with both TFIID and RNA polymerase II: interactions
between two members of the TET family, EWS and hTAFII68, and subunits of
TFIID and RNA polymerase II complexes, Mol. Cell. Biol. 18 (1998) 1489–1497.
[5] Z. Zhou, L.J. Licklider, S.P. Gygi, R. Reed, Comprehensive proteomic analysis of the
human spliceosome, Nature 419 (2002) 182–185.
[6] A.Y. Tan, J.L. Manley, TLS inhibits RNA polymerase III transcription, Mol. Cell. Biol.
30 (2010) 186–196.
[7] Y. Kanai, N. Dohmae, N. Hirokawa, Kinesin transports RNA: isolation and charac-
terization of an RNA-transporting granule, Neuron 43 (2004) 513–525.
[8] X. Lui, C. Niu, J. Ren, J. Zhang, X.X. Xie, H. Zhu, W. Feng, W. Gong, The RRM domain
of human fused in sarcoma protein reveals a non-canonical nucleic acid binding
site, Biochem. Biophys. Acta 1832 (2013) 375–385.
[9] A. Olofsson, H. Willen, M. Goransson, K. Engstrom, J.M. Meis-Kindblom, G.
Stenman, L.G. Kindblom, P. Aman, Abnormal expression of cell cycle regulators
in FUS-CHOP carrying liposarcomas, Int. J. Oncol. 25 (2004) 1349–1355.
[10] A.Y. Tan, J.L. Manley, TLS/FUS: a protein in cancer and ALS, Cell Cycle 11 (2012)
3349–3350.
[11] C. Lagier-Tourenne, M. Polymenidou, D.W. Cleveland, TDP-43 and FUS/TLS: emerging
roles in RNA processing and neurodegeneration, Hum.Mol. Genet. 19 (2010) R46–R64.
[12] D. Dormann, R. Rodde, D. Edbauer, E. Bentmann, I. Fischer, A. Hruscha, M.E. Than,
I.R. Mackenzie, A. Capell, B. Schmid, M. Neumann, C. Haass, ALS-associated fused
in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import, EMBO
J. 29 (2010) 2841–2857.[13] J. Gal, J. Zhang, D.M. Kwinter, J. Zhai, H. Jia, J. Jia, H. Zhu, Nuclear localization se-
quence of FUS and induction of stress granules by ALS mutants, Neurobiol.
Aging 32 (2011) 2323.e27–2323.e40.
[14] D.A. Bosco, N. Lemay, H.K. Ko, H. Zhou, C. Burke, T.J. Kwiatkowski Jr., P. Sapp, D.
McKenna-Yasek, R.H. Brown Jr., L.J. Hayward, Mutant FUS proteins that cause
amyotrophic lateral sclerosis incorporate into stress granules, Hum. Mol. Genet.
19 (2010) 4160–4175.
[15] R. Xia, Y. Liu, L. Yang, J. Gal, H. Zhu, J. Jia, Motor neuron apoptosis and neuromus-
cular junction perturbation are prominent features in a Drosophila model of
Fus-mediated ALS, Mol. Neurodegener. 7 (2012) 10.
[16] J.W. Wang, J.R. Brent, A. Tomlinson, N.A. Shneider, B.D. McCabe, The ALS-associated
proteins FUS and TDP-43 function together to affect Drosophila locomotion and life
span, J. Clin. Invest. 121 (2011) 4118–4126.
[17] Y. Chen, M. Yang, J. Deng, X. Chen, Y. Ye, L. Zhu, J. Liu, H. Ye, Y. Shen, Y. Li, E.J. Rao,
K. Fushimi, X. Zhou, E.H. Bigio, M. Mesulam, Q. Xu, J.Y. Wu, Expression of human
FUS protein in Drosophila leads to progressive neurodegeneration, Protein Cell 2
(2011) 477–486.
[18] B. Rogelj, L.E. Easton, G.K. Bogu, L.W. Stanton, G. Rot, T. Curk, B. Zupan, Y.
Sugimoto, M. Modic, N. Haberman, J. Tollervey, R. Fujii, T. Takumi, C.E. Shaw, J.
Ule, Widespread binding of FUS along nascent RNA regulates alternative splicing
in the brain, Sci. Rep. 2 (2012) 603.
[19] C. Lagier-Tourenne, M. Polymenidou, K.R. Hutt, A.Q. Vu, M. Baughn, S.C. Huelga,
K.M. Clutario, S.C. Ling, T.Y. Liang, C. Mazur, E. Wancewicz, A.S. Kim, A. Watt, S.
Freier, G.G. Hicks, J.P. Donohue, L. Shiue, C.F. Bennett, J. Ravits, D.W. Cleveland,
G.W. Yeo, Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect
in processing long pre-mRNAs, Nat. Neurosci. 15 (2012) 1488–1497.
[20] J.I. Hoell, E. Larsson, S. Runge, J.D. Nusbaum, S. Duggimpudi, T.A. Farazi, M. Hafner,
A. Borkhardt, C. Sander, T. Tuschl, RNA targets of wild-type and mutant FET family
proteins, Nat. Struct. Mol. Biol. 18 (2011) 1428–1431.
[21] K. Kapur, H. Jiang, Y. Xing, W.H. Wong, Cross-hybridization modeling on
Affymetrix exon arrays, Bioinformatics 24 (2008) 2887–2893.
[22] S. Shen, C.C. Warzecha, R.P. Carstens, Y. Xing, MADS+: discovery of differential
splicing events from Affymetrix exon junction array data, Bioinformatics 26
(2010) 268–269.
[23] T. Okabe, T. Nakamura, Y.N. Nishimura, K. Kohu, S. Ohwada, Y. Morishita, T.
Akiyama, RICS, a novel GTPase-activating protein for Cdc42 and Rac1, is involved
in the beta-catenin-N-cadherin and N-methyl-D-aspartate receptor signaling, J. Biol.
Chem. 278 (2003) 9920–9927.
[24] M. Tateno, H. Sadakata, M. Tanaka, S. Itohara, R.M. Shin, M. Miura, M. Masuda, T.
Aosaki, M. Urushitani, H. Misawa, R. Takahashi, Calcium-permeable AMPA recep-
tors promote misfolding of mutant SOD1 protein and development of
amyotrophic lateral sclerosis in a transgenic mouse model, Hum. Mol. Genet. 13
(2004) 2183–2196.
[25] A.S. Leonard, I.A. Lim, D.E. Hemsworth, M.C. Horne, J.W. Hell, Calcium/calmodulin-
dependent protein kinase II is associated with the N-methyl-D-aspartate receptor,
Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 3239–3244.
